KLK3 and pachyonychia congenita: The first and only FDA-approved urinary biomarker for PC is the Progensa Prostate Cancer Antigen 3 (PCA3) assay, which measures the concentration of PCA3 and PSA messenger RNAs (mRNA) levels by transcription-mediated amplification, using 2.5 mL of post-DRE urine.